RT
Retham Technologies, Inc.
United States · Healthtech
Retham is developing HITDx, a functional hospital-lab assay for heparin-induced thrombocytopenia that uses stable cryopreserved donor platelets to make clinically relevant platelet testing more practical; the diagnostic is in validation and regulatory development, while its cryopreserved platelets are available for research use.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.5M | Talents Fund — LeadGolden Angels Investors — ParticipantMilwaukee Venture Partners — Participant |